IN BRIEF: MGC Pharmaceuticals applies for cannabinoid patent

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Submits Self-Nano ...

Alliance News 15 July, 2021 | 5:15PM
Email Form Facebook Twitter LinkedIn RSS

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Submits Self-Nano Emulsifying Cannabinoids-Ionic Complex Concentrate Drug Delivery System to the Slovenian Intellectual Property Office. MGC Pharma expects the patent to be issued within the next 12 months.

Co-founder and Managing Director Roby Zomer comments: "The acceptance of this patent could be transformational for patients who need treatment and therapeutic relief from neurological diseases. The new IP will not only improve MGC Pharma's current formulations, including our phytocannabinoid-based drugs CannEpil and CogniCann, but potentially provide more affordable medicines for patients as a result of the more efficient use of resources in formulations.

"The submission to SIPO provides MGC Pharma with the right to file further applications in multiple jurisdictions and treat people and patients suffering from these conditions on a global scale."

Current stock price: 2.05 pence

Year-to-date change: up 39% from February IPO price of 1.48p

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
MGC Pharmaceuticals Ltd 21.00 GBX 0.00 -
MGC Pharmaceuticals Ltd 0.41 AUD 5.19 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures